Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bacterial lysates to prevent lower respiratory infections and wheeze in late-moderate preterm infants
NL-OMON60098Phase 3Recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Dec 2024
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of lyophilized bacterial lysates in pulmonary infection (3 arms), sponsored by Franciscus Gasthuis & Vlietland. Primary endpoints: Protea-1 and Protea-2. Started Dec 2024; status: recruiting.
02
Drugs
lyophilized bacterial lysates
03
Conditions
pulmonary infection
Beyond the preview
Go deeper on NL-OMON60098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60098.